Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
Essential Resources
Provider Information
Patient Information
From Our Sponsors
Neurocrine Biosciences CAHtalyst Adult Phase 3 Clinical Trial Meets All Endpoints in Congenital Adrenal Hyperplasia, Published in NEJM
The registrational clinical trial met all endpoints related to androgen reduction and glucocorticoid dose reduction while maintaining androgen control.
FDA Grants Breakthrough Therapy Designation for Oral Congenital Adrenal Hyperplasia Medication
Crinecerfont was granted FDA breakthrough therapy designation for the treatment of congenital adrenal hyperplasia.
